PMID- 31966521
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200126
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 10
IP  - 12
DP  - 2017
TI  - Promoter hypermethylation of PIEZO2 is a risk factor and potential clinical 
      biomarker for laryngeal squamous cell carcinoma.
PG  - 11635-11643
AB  - The aim of this study was to investigate the association between piezo type 
      mechanosensitive ion channel component 2 (PIEZO2)-promoter methylation with and 
      its clinical value for laryngeal squamous cell carcinoma (LSCC). Quantitative 
      methylation-specific polymerase chain reaction technology was applied to measure 
      PIEZO2 promoter methylation levels from 99 LSCC patients. Inclusive in the 
      analysis were 133 (117 LSSC and 16 normal) samples from The Cancer Genome Atlas 
      (TCGA). Our results showed significantly higher levels of PIEZO2 promoter 
      methylation in LSCC than normal tissues (our cohort: P = 2.94E-21; TCGA cohort: P 
      = 1.07E-19). In addition, PIEZO2 methylation was significantly associated with 
      gender, differentiation, tumor (T) stage, lymph node metastasis, and clinical 
      stage. The areas under the receiver characteristic curves (AUCs) based on our 
      cohort and TCGA cohort were 0.917 and 0.978, respectively. Meanwhile, our study 
      confirmed that PIEZO2 promoter hypermethylation could independently predict a 
      poorer overall survival of LSCC patients (hazard ratio = 6.671; 95% confidence 
      interval = 2.087-21.324). In conclusion, our study revealed that PIEZO2 promoter 
      hypermethylation was a risk factor and might be involved in progression and 
      metastasis, as well as serve as a potential clinical biomarker of LSCC.
CI  - IJCEP Copyright (c) 2017.
FAU - Cheng, Lixin
AU  - Cheng L
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University Ningbo, Zhejiang, China.
FAU - Shen, Zhisen
AU  - Shen Z
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University Ningbo, Zhejiang, China.
FAU - Zhou, Chongchang
AU  - Zhou C
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University Ningbo, Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20171201
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
PMC - PMC6966076
OTO - NOTNLM
OT  - LSCC
OT  - PIEZO2
OT  - diagnosis
OT  - metastasis
OT  - methylation
OT  - prognosis
COIS- None.
EDAT- 2017/12/01 00:00
MHDA- 2017/12/01 00:01
PMCR- 2017/12/01
CRDT- 2020/01/23 06:00
PHST- 2017/11/09 00:00 [received]
PHST- 2017/11/22 00:00 [accepted]
PHST- 2020/01/23 06:00 [entrez]
PHST- 2017/12/01 00:00 [pubmed]
PHST- 2017/12/01 00:01 [medline]
PHST- 2017/12/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2017 Dec 1;10(12):11635-11643. eCollection 2017.